Fast Track Designation for Xilonix for Cachexia
XBiotech announced that the company has been granted Fast Track designation for its anti-cachexia drug, Xilonix.
XBiotech announced that the company has been granted Fast Track designation for its anti-cachexia drug, Xilonix.
Pregnant women with current or past eating disorders have few adverse perinatal outcomes.
Patients with anorexia nervosa (AN) tend to overestimate the size of their body but not the bodies of others, basing their weight and body dimensions on their pre-AN body dimensions.
Pregnant women who fast during the month of Ramadan do not have an increased risk of preterm delivery, regardless of when during gestation the fasting occurs.
While the infant mortality rate, premature births, and teen births are declining, more children are living in poverty.
Although some progress has been made toward meeting Millennium Development Goal 1 (MDG 1) in developing countries, the chances of these countries as a whole meeting the goal are <5%.
For women aged 50 years and older there is wide endorsement of weight and shape concerns and of eating disorder symptoms, dieting, and body checking behaviors.
Even a short period of moderate or severe undernutrition or famine during childhood or adolescence can increase the risk of developing type 2 diabetes in adulthood.
Pleasure eating is associated with increased peripheral levels of two endogenous rewarding mediators.